Urinary concentrations of colistimethate and formed colistin after intravenous administration in patients with multidrug-resistant gram-negative bacterial infections

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 8, 2017, Pages

  Luque, Sonia ^a   Escaño, Carol ^a   Sorli, Luisa ^a,d   Li, Jian ^c   Campillo, Nuria ^a   Horcajada, Juan Pablo ^a,d   Salas, Esther ^a   Grau, Santiago ^a,b  

^a HOSPITAL DEL MAR   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c MONASH UNIVERSITY   (Australia)

^d UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

Colistin; Gram negative bacteria; Pharmacokinetics; Urinary tract infections

Indexed keywords

AMIKACIN; COLISTIMETHATE; COLISTIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; VANCOMYCIN; ANTIINFECTIVE AGENT; COLISTINMETHANESULFONIC ACID;

ABDOMINAL INFECTION; ADULT; AGED; ARTICLE; BACTERIAL STRAIN; CLINICAL ARTICLE; DRUG URINE LEVEL; ENTEROCOCCUS FAECALIS; FEMALE; GRAM NEGATIVE INFECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; MINIMUM INHIBITORY CONCENTRATION; MINIMUM PLASMA CONCENTRATION; MULTIDRUG RESISTANCE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFECTION; SKIN INFECTION; SOFT TISSUE INFECTION; URINARY EXCRETION; URINARY TRACT INFECTION; VERY ELDERLY; ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANALOGS AND DERIVATIVES; DRUG EFFECTS; INTRAVENOUS DRUG ADMINISTRATION; MICROBIOLOGY; PSEUDOMONAS INFECTION; URINE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; URINARY TRACT INFECTIONS;

EID: 85026432273     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02595-16     Document Type: Article

References (21)

1. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, Paterson DL. 2006. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 6:589. https://doi.org/10.1016/S1473-3099(06)70580-1.
2. Grégoire N, Mimoz O, Mégarbane B, Comets E, Chatelier D, Lasocki S, Gauzit R, Balayn D, Gobin P, Marchand S, Couet W. 2014. New colistin population pharmacokinetic data in critically ill patients suggesting an alternative loading dose rationale. Antimicrob Agents Chemother 58: 7324–7330. https://doi.org/10.1128/AAC.03508-14.
3. Yapa WS, Li J, Patel K, Wilson JW, Dooley MJ, George J, Clark D, Poole S, Williams E, Porter CJ, Nation RL, McIntosh MP. 2014. Pulmonary and systemic pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic fibrosis patients: targeting advantage of inhalational administration. Antimicrob Agents Chemother 58:2570–2579. https://doi.org/10.1128/AAC.01705-13.
4. Koomanachai P, Landersdorfer CB, Chen G, Lee HJ, Jitmuang A, Wasuwattakul S, Sritippayawan S, Li J, Nation RL, Thamlikitkul V. 2014. Pharmacokinetics of colistin methanesulfonate and formed colistin in end-stage renal disease patients receiving continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother 58:440–446. https://doi.org/10.1128/AAC.01741-13.
5. Jitmuang A, Nation RL, Koomanachai P, Chen G, Lee HJ, Wasuwattakul S, Sritippayawan S, Li J, Thamlikitkul V, Landersdorfer CB. 2015. Extracor-poreal clearance of colistin methanesulphonate and formed colistin in end-stage renal disease patients receiving intermittent haemodialysis: implications for dosing. J Antimicrob Chemother 70:1804–1811. https://doi.org/10.1093/jac/dkv031.
6. Ratjen F, Rietschel E, Kasel D, Schwiertz R, Starke K, Beier H, van Koningsbruggen S, Grasemann H. 2006. Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. J Antimicrob Chemother 57:306–311. https://doi.org/10.1093/jac/dki461.
7. Sorlí L, Luque S, Grau S, Berenguer N, Segura C, Montero MM, Alvarez-Lerma F, Knobel H, Benito N, Horcajada JP. 2013. Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study. BMC Infect Dis 13:380. https://doi.org/10.1186/1471-2334-13-380.
8. Garonzik SM, Li J, Thamlikitkul V, Paterson DL, Shoham S, Jacob J, Silveira FP, Forrest A, Nation RL. 2011. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 55:3284 –3294. https://doi.org/10.1128/AAC.01733-10.
9. Li J, Coulthard K, Milne R, Nation RL, Conway S, Peckham D, Etherington C, Turnidge J. 2003. J Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. J Antimicrob Chemother 52:987–992. https://doi.org/10.1093/jac/dkg468.
10. Luque S, Grau S, Valle M, Sorlí L, Horcajada JP, Segura C, Alvarez-Lerma F. 2013. Differences in pharmacokinetics and pharmacodynamics of colistimethate sodium (CMS) and colistin between three different CMS dosage regimens in a critically ill patient infected by a multidrug-resistant Acinetobacter baumannii. Int J Antimicrob Agents 42:178–181. https://doi.org/10.1016/j.ijantimicag.2013.04.018.
11. Markou N, Fousteri M, Markantonis SL, Boutzouka E, Tsigou E, Baltopoulo G. 2011. Colistin penetration in the alveolar lining fluid of critically ill patients treated with IV colistimethate sodium. Chest 139:232–233. https://doi.org/10.1378/chest.10-1860.
12. Plachouras D, Karvanen M, Friberg LE, Papadomichelakis E, Antoniadou A, Tsangaris I, Karaiskos I, Poulakou G, Kontopidou F, Armaganidis A, Cars O, Giamarellou H. 2009. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 53:3430 –3436. https://doi.org/10.1128/AAC.01361-08.
13. Boisson M, Jacobs M, Grégoire N, Gobin P, Marchand S, Couet W, Mimoz O. 2014. Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients. Antimicrob Agents Chemother 58:7331–7339. https://doi.org/10.1128/AAC.03510-14.
14. Couet W, Grégoire N, Gobin P, Saulnier PJ, Frasca D, Marchand S, Mimoz O. 2011. Pharmacokinetics of colistin and colistimethate sodium after a single 80-mg intravenous dose of CMS in young healthy volunteers. Clin Pharmacol Ther 89:875–879. https://doi.org/10.1038/clpt.2011.48.
15. Gobin P, Lemaître F, Marchand S, Couet W, Olivier JC. 2010. Assay of colistin and colistin methanesulfonate in plasma and urine by liquid chromatography-tandem mass spectrometry. Antimicrob Agents Chemother 54:1941–1948. https://doi.org/10.1128/AAC.01367-09.
16. Froman J, Gross L, Curatola S. 1970. Serum and urine levels following parenteral administration of sodium colistimethate to normal individuals. J Urol 103:210–214.
17. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P, ADQI Workgroup. 2004. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 8:R204–R212. https://doi.org/10.1186/cc2872.
18. Li J, Milne RW, Nation RL, Turnidge JD, Smeaton TC, Coulthard K. 2004. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. J Antimicrob Chemother 53:837–840. https://doi.org/10.1093/jac/dkh167.
19. Nation RL, Li J. 2009. Colistin in the 21st century. Curr Opin Infect Dis 22:535–543. https://doi.org/10.1097/QCO.0b013e328332e672.
20. Li J, Milne RW, Nation RL, Turnidge JD, Coulthard K, Johnson DW. 2001. A simple method for the assay of colistin in human plasma, using pre-column derivatization with 9-fluorenylmethyl chloroformate in solid-phase extraction cartridges and reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 761:167–175. https://doi.org/10.1016/S0378-4347(01)00326-7.
21. Li J, Milne RW, Nation RL, Turnidge JD, Coulthard K, Valentine J. 2002. Simple method for assaying colistin methanesulfonate in plasma and urine using high-performance liquid chromatography. Antimicrob Agents Chemother 46:3304–3307. https://doi.org/10.1128/AAC.46.10.3304-3307.2002.